UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Ra'anana, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:URGN
CUSIPN/A
Phone972-9770-7601
Debt
Debt-to-Equity RatioN/A
Current Ratio23.28
Quick Ratio23.22
Price-To-Earnings
Trailing P/E Ratio-20.09
Forward P/E Ratio-11.56
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.16 million
Price / Sales72.44
Cash FlowN/A
Price / CashN/A
Book Value$4.98 per share
Price / Book8.63
Profitability
EPS (Most Recent Fiscal Year)($2.14)
Net Income$-20,000,000.00
Net MarginsN/A
Return on Equity-35.54%
Return on Assets-33.35%
Miscellaneous
Employees46
Outstanding Shares13,750,000
Market Cap$644.66 million
Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions
What is Urogen Pharma's stock symbol?
Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."
How were Urogen Pharma's earnings last quarter?
Urogen Pharma Ltd (NASDAQ:URGN) released its earnings results on Tuesday, August, 14th. The company reported ($1.14) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.89) by $0.25. The business had revenue of $0.36 million for the quarter. View Urogen Pharma's Earnings History.
When is Urogen Pharma's next earnings date?
What price target have analysts set for URGN?
7 equities research analysts have issued 12 month price targets for Urogen Pharma's stock. Their predictions range from $37.00 to $75.00. On average, they anticipate Urogen Pharma's stock price to reach $57.00 in the next year. This suggests a possible upside of 32.6% from the stock's current price. View Analyst Price Targets for Urogen Pharma.
What is the consensus analysts' recommendation for Urogen Pharma?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Urogen Pharma.
What are Wall Street analysts saying about Urogen Pharma stock?
Here are some recent quotes from research analysts about Urogen Pharma stock:
- 1. According to Zacks Investment Research, "UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. " (5/15/2018)
- 2. Cowen Inc analysts commented, "URGN presented updates for MitoGel’s Phase 3 OLYMPUS trial (topline data in 2Q18)." (11/15/2017)
Who are some of Urogen Pharma's key competitors?
Some companies that are related to Urogen Pharma include Supernus Pharmaceuticals (SUPN), Global Blood Therapeutics (GBT), Myokardia (MYOK), Akorn (AKRX), Spectrum Pharmaceuticals (SPPI), Xencor (XNCR), Cambrex (CBM), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Phibro Animal Health (PAHC), Prestige Brands (PBH), Portola Pharmaceuticals (PTLA), G1 Therapeutics (GTHX), Mirati Therapeutics (MRTX) and Pacira Pharmaceuticals (PCRX).
Who are Urogen Pharma's key executives?
Urogen Pharma's management team includes the folowing people:
- Mr. Ron Bentsur, CEO & Director (Age 52)
- Mr. Stephen Mullennix, Interim CFO & COO
- Ms. Catherine Bechtold, Director of Corp. Communications and Investor Relations
- Ms. Christine Cassiano, Corp. Affairs Officer
- Dr. Sari Prutchi-Sagiv Ph.D., Marketing Director
When did Urogen Pharma IPO?
(URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.
Has Urogen Pharma been receiving favorable news coverage?
News coverage about URGN stock has been trending somewhat positive this week, according to Accern. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Urogen Pharma earned a news impact score of 0.11 on Accern's scale. They also assigned press coverage about the company an impact score of 47.20 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Urogen Pharma.
Who are Urogen Pharma's major shareholders?
Urogen Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Menora Mivtachim Holdings LTD. (18.18%), ARKIN MOSHE (9.37%), ProQuest Associates IV LLC (5.74%), FMR LLC (5.14%), Citadel Advisors LLC (2.33%) and Clal Insurance Enterprises Holdings Ltd (2.25%). View Institutional Ownership Trends for Urogen Pharma.
Which institutional investors are selling Urogen Pharma stock?
URGN stock was sold by a variety of institutional investors in the last quarter, including ProQuest Associates IV LLC, FMR LLC, DSAM Partners London Ltd, Renaissance Technologies LLC, Alps Advisors Inc., Alps Advisors Inc. and ARK Investment Management LLC. View Insider Buying and Selling for Urogen Pharma.
Which institutional investors are buying Urogen Pharma stock?
URGN stock was bought by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., Citadel Advisors LLC, BlackRock Inc., Bainco International Investors, Wildcat Capital Management LLC, Clal Insurance Enterprises Holdings Ltd, Mckinley Capital Management LLC Delaware and Swiss National Bank. View Insider Buying and Selling for Urogen Pharma.
How do I buy shares of Urogen Pharma?
Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Urogen Pharma's stock price today?
One share of URGN stock can currently be purchased for approximately $42.99.
How big of a company is Urogen Pharma?
Urogen Pharma has a market capitalization of $644.66 million and generates $8.16 million in revenue each year. The company earns $-20,000,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Urogen Pharma employs 46 workers across the globe.
How can I contact Urogen Pharma?
Urogen Pharma's mailing address is 9 Ha'Ta'asiya Street, Ra'anana L3, 4365007. The company can be reached via phone at 972-9770-7601 or via email at [email protected]
MarketBeat Community Rating for Urogen Pharma (NASDAQ URGN)
MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
